SRPT,CRWG,UNRH,MITK,ZIOP,UNRH,RENN,MAXD,SFIN,ZAGG -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents14 hours ago

    Edited Transcript of SRPT earnings conference call or presentation 8-Aug-18 8:30pm GMT

    Q2 2018 Sarepta Therapeutics Inc Earnings Call

  • GuruFocus.comyesterday

    Weekly CEO Buys Highlight

    Insiders invest in Penn National Gaming, Sarepta Therapeutics, News Corp., e.l.f. Beauty and New Media Investment Group

  • Is ZAGG Inc (NASDAQ:ZAGG) Undervalued?
    Simply Wall St.3 days ago

    Is ZAGG Inc (NASDAQ:ZAGG) Undervalued?

    ZAGG Inc (NASDAQ:ZAGG), a consumer durables company based in United States, saw a decent share price growth in the teens level on the NasdaqGS over the last few months. AsRead More...

  • Benzinga4 days ago

    Jim Cramer Weighs In On NuStar Energy, Royal Dutch Shell, United Rentals And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said it's time to buy the oil companies because crude oil is going to $80. He thinks Royal Dutch Shell plc (ADR) ADR Class A (NYSE: RDS-A ) ...

  • Market Exclusive5 days ago

    Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail

    Futures Up on China-U.S. Trade Talks, China at New 52-Week Lows Washington sent an invitation to Beijing for trade talks in late August, and the Chinese have responded in kind. They plan to send their vice minister of commerce to discuss the situation, and U.S. futures are up on the news. Not so much for […] The post Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail appeared first on Market Exclusive.

  • TheStreet.com6 days ago

    Prepare For the Worst but Stay Positive

    The indices have bounced off the intraday lows but when a bounce doesn't occur quickly after the open the danger of a poor close is higher. This is a market that has been struggling for a while although the indices have covered it to a great extent.

  • TheStreet.com7 days ago

    Little Fear of Missing Out as Stocks Hold Gains

    On Twitter this morning Tony Dwyer commented that "According to NFIB, Small Biz Optimism Index hit 107.9 in July, which is just 0.1% from record reading in 1983. There is no way to spin this as negative since data started (1974), we found NFIB Index peak leads recession by median 41 months" In other words, business optimism is booming and when it is this positive the likelihood of a recession in the near term is very small. The stock market doesn't always correlate with the economy but it is hard to develop a 'topping' thesis when the economic trend is so solid.

  • TheStreet.com8 days ago

    Overly Aggressive Dip Buyers Finally Trapped

    It has worked so consistently for so long that it has become a bit of a joke in the trading community. Bad news such as terrorist attacks, nuclear war with Korea, Trade wars with China and even President Donald Trump himself have consistently result in automatic and energetic buying.

  • See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Sarepta Therapeutics Inc NASDAQ/NGS:SRPT

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool10 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these fast-rising biotech stocks keep the momentum going?

  • InvestorPlace11 days ago

    GlycoMimetics Stock Has Substantial Upside

    GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.

  • Is Sarepta Therapeutics Stock a Bargain?
    Motley Fool11 days ago

    Is Sarepta Therapeutics Stock a Bargain?

    Sarepta's shares finally pulled back last month. Is it time to buy?

  • Why Sarepta Therapeutics, Inc. Stock Surged Today
    Motley Fool12 days ago

    Why Sarepta Therapeutics, Inc. Stock Surged Today

    Better-than-expected second quarter results lit a fire beneath the high-flying biotech stock.

  • Why Ziopharm Oncology Is Soaring 14% Today
    Motley Fool12 days ago

    Why Ziopharm Oncology Is Soaring 14% Today

    The company's second-quarter update is fueling optimism.

  • Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
    Market Realist12 days ago

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.

  • Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales
    Zacks12 days ago

    Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales

    Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.

  • Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
    Zacks12 days ago

    Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options

    Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.

  • What Analysts Recommend for Ionis after Q2 2018
    Market Realist12 days ago

    What Analysts Recommend for Ionis after Q2 2018

    Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.

  • Ziopharm Oncology (ZIOP) Reports Q2 Loss, Lags Revenue Estimates
    Zacks13 days ago

    Ziopharm Oncology (ZIOP) Reports Q2 Loss, Lags Revenue Estimates

    Ziopharm (ZIOP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press13 days ago

    Ziopharm: 2Q Earnings Snapshot

    The Boston-based company said it had a loss of 12 cents per share. The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for a loss ...

  • Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
    Zacks13 days ago

    Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

    Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 8.51% and 3.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press13 days ago

    Sarepta Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.67. Losses, adjusted for non-recurring costs and stock option expense, were 43 cents per share. The results exceeded ...

  • How Ionis’s Q2 2018 Earnings Trended
    Market Realist13 days ago

    How Ionis’s Q2 2018 Earnings Trended

    Ionis Pharmaceuticals (IONS), one of the leading biopharmaceutical companies, is focused on developing RNA-targeted therapies. Ionis has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. Ionis missed Wall Street analyst estimates and reported earnings per share of -$0.29 on revenues of $117.7 million during Q2 2018 as compared to EPS estimates of -$0.09 on revenues of $135.5 million during the quarter.

  • See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 12. Over the last one-month, outflows of investor capital in ETFs holding SRPT totaled $1.58 billion.

  • Why Ziopharm Oncology Stock Zoomed 16.8% Higher Today
    Motley Fool14 days ago

    Why Ziopharm Oncology Stock Zoomed 16.8% Higher Today

    A game of musical chairs on its board of directors causes investors to sing a new tune about this beaten-down biotech.